MedPath

A Comparison Of Nebulisation With Dexmedetomidine And Nebulisation With 4% Lignocaine Plus Dexmedetomidine For Awake Fibreoptic Intubatio

Phase 2
Conditions
Health Condition 1: - Health Condition 2: O- Medical and Surgical
Registration Number
CTRI/2021/10/037256
Lead Sponsor
Indira Gandhi institute of medical sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

patient consent, ASA grade 1 and 2, patient with anticipated difficult intubation(LEMON >2), BMI >30 kg/m2

Exclusion Criteria

patient refusal, airway hypersensitivity, allergy to drugs used (lignocaine/dexmedetomidine),epileptic patients,patients with poor cardiopulmonary reserve, bleeding tendency, obesity, other co-morbid conditions

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.sedation/alertness(OAA SCORE) <br/ ><br>2.vocal cord movement(%) <br/ ><br>3.limb movement <br/ ><br>4.fibreoptic intubation score <br/ ><br>5.coughingTimepoint: 0 to 5 min
Secondary Outcome Measures
NameTimeMethod
1) To compare the hemodynamic changes of two groups <br/ ><br>2) Dose sparing effect of propofolTimepoint: 0 min,1 min, 2 min , 3 min, 4 min, 5 min
© Copyright 2025. All Rights Reserved by MedPath